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Anesthetizing the Fibrillating Heart
Peter Hanna, MD; Ching Zhu, MD; Pradeep S. Rajendran, PhD; Kalyanam Shivkumar, MD, PhD
T here is increasing interest in neuromodulation as anantiarrhythmic therapy. The autonomic nervous system
plays a prominent role in the regulation of normal cardiac
physiological feature and is composed of a hierarchy of
extrinsic and intrinsic components.1 Extrinsic components are
housed within the central nervous system and the intratho-
racic extracardiac ganglia. Interventions that have been
performed on the extrinsic components for the treatment of
cardiovascular disease include cervical vagus nerve stimula-
tion (VNS) for heart failure and stellate ganglionectomy for
refractory ventricular arrhythmia.2,3
The intrinsic cardiac nervous system (ICNS) is composed of
a complex network of neurons at the level of the heart,
organized in ganglionated plexi (GPs) that are located in
epicardial fat pads. These GPs are found at the atria, primarily
around the pulmonary veins, and around the base of the aorta
and pulmonary trunk and contain a mixture of cell bodies and
axons of afferent, parasympathetic, and sympathetic efferent
or interconnecting neurons.1,4 The role of ICNS at the level of
the heart in the initiation and maintenance of atrial fibrillation
(AF) has been a subject of ongoing investigations. Canine
models of AF demonstrate an increase in ICNS activity before
AF episodes,5 and, in humans, changes in autonomic tone
before AF episodes, as determined by heart rate variability
analyses, further support the role of the autonomic nervous
system in human AF.6 Carlson et al demonstrated that
stimulation of the right atrial GP in human patients could
induce sinus slowing,7 and a subsequent study showed that
right atrial GP stimulation affects atrial conduction times.8 In
addition to imposing changes in atrial electrophysiological
features, stimulation of ganglia in the fat pad by the right
superior pulmonary vein facilitates AF inducibility in canine
hearts by providing a substrate for pulmonary venous firing to
result in AF.9 Following from these studies, interventions of
the ICNS in AF have been explored. In a canine model,
Schauerte et al showed that radiofrequency ablation via an
endocardial approach could target atrial parasympathetic
nerves to inhibit vagally mediated AF.10 Subsequent study in
human patients with AF illustrated that adjunctive GP ablation
with catheter-based AF ablation resulted in higher success
rates.11 More recently, intraoperative injection of botulinum
toxin type A has been studied for mitigation of risk of
postcardiac surgery AF.12,13
These prior studies evaluated neuromodulation of GPs in
patients with paroxysmal AF or in those who were at risk for
postoperative AF. In this issue of the Journal of the American
Heart Association (JAHA), Lee et al investigate whether
injections of neuronal blocker lidocaine into the epicardial
fat pads of patients with persistent and long-standing
persistent AF affect atrial electrophysiological features.14 To
determine efficacy, the investigators first injected lidocaine
into the epicardial fat pads of dogs during sinus rhythm and
found that AF could no longer be induced in 4 of the 7 dogs in
a VNS AF model. Subsequently, in 6 patients with persistent
or long-standing AF undergoing coronary artery bypass
grafting or valvular surgery, epicardial fat pads were injected
with lidocaine. Electrograms were recorded across the atria
using an electrode array and were characterized by shorter
left than right atrial mean cycle lengths at baseline, with a left-
right dominant frequency gradient. Although AF persisted in
all patients after lidocaine injection, the left atrial cycle
lengths prolonged with disappearance of the left-right dom-
inant frequency gradient.
The investigators provide important evidence that mod-
ulating the GPs exerts effects on atrial electrophysiological
features in human AF. Although studies evaluating adjunc-
tive GP ablation or botulinum toxin injection reported
outcomes on freedom from AF,11–13 this study is unique
in providing real-time evidence of GP involvement in atrial
electrophysiological features while in AF. As the investiga-
tors point out, this finding is consistent with the loss of
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left-right frequency gradient observed with AF ablation.15
However, it remains to be seen how successful such an
approach would be in patients with persistent forms of AF
and who may have significant electrical and structural
remodeling of cardiac tissue. In this study, no patients had
conversion to sinus rhythm with lidocaine injections at the
GPs, and whether fine-tuning the neuromodulatory strategy
could bring about successful treatment of AF is an
unanswered question.
The ideal approach to neuromodulation of GPs is unclear.
Acute ischemia and myocardial infarction studies in canine
models have indicated that GP ablations may affect
ventricular electrophysiological features to increase ventric-
ular arrhythmia inducibility.16,17 In humans, the AFACT
(Atrial Fibrillation Ablation and Autonomic Modulation via
Thorascopic Surgery) study raised concerns about radiofre-
quency ablation of major GPs.18 In this prospective,
randomized controlled study, patients with long-standing
AF, enlarged atria, or failed catheter ablation underwent
epicardial ablation of the 4 major GPs and the ligament of
Marshall GP group at time of thorascopic AF surgery.
However, not only did GP ablation fail to reduce AF
recurrence, but it was also associated with increased
adverse events. Most notably, 10% of the patients in the GP
ablation group sustained sinus node dysfunction, half of
whom required pacemaker implantation, compared with 3%
in the placebo group. The unintended consequence of
affecting sinus node function may have been caused by off-
target ablative effects on the myocardium (or perhaps injury
to the ICNS), and the authors conclude that a neuroablative
strategy using radiofrequency energy should not be adopted
in such patients. In contrast to these results, endocardial
catheter ablation of the 4 major GP groups has had
promising results in the treatment of sinus bradycardia,
particularly in younger patients.19 Additional study will be
required to determine the exact role of neuroablation at the
level of the heart.
If a neuromodulatory approach through chemical means
proves advantageous, the ideal agent is unknown. Reassur-
ingly, in contrast to the AFACT study, none of the patients in
the 2 studies on botulinum toxin injections in the GPs
developed sinus node dysfunction. However, the 2 studies
yielded disparate results, with one showing sustained reduc-
tion in AF rates while the other showed no discernible
difference in freedom from AF12,13; the reason for the differing
results is unclear. Understanding the physiological features
and the elements of the GPs that should be targeted may help
guide the ideal neuromodulatory agent. In particular, GPs
contain axons “en passant” to other regions of the heart and
neuronal cell bodies with connections to not only the
myocardium but also other neurons within cardiac ganglia
and interganglionic connections. Use of a ganglionic blocker in
place of the axonal blocker lidocaine may delineate which
aspect of the GP modification provides benefit and may help
tailor the intervention. For example, using such an approach,
Fee et al were able to show differential effects of VNS when
using a ganglionic versus an axonal blocker.20 In a canine
model, these investigators showed that injection of ganglionic
blocker C6 had little effect on sinus slowing or atrioventricular
block with cervical VNS. In contrast, injection of axonal blocker
lidocaine resulted in a reduction in the atrioventricular block
during left cervical VNS. Detailed studies such as this may
discern whether neuromodulation targeting neuronal cell
bodies or axons of passage are required to bring about a
desired effect and whether such an approach could mitigate
off-target effects.
The current study highlights that neuromodulation of the
ICNS affects atrial electrophysiological features in a manner
akin to that of AF ablation. Whether these findings can be
extended as a treatment for AF without the off-target effects
of radiofrequency ablative techniques remains to be seen.
Identifying the components of the GPs involved in the
pathogenesis of AF and understanding the functional signif-
icance of cardiac neuroanatomical features could promote the
development of a targeted therapeutic strategy for AF.
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